Get the Stockscreener App
39.10
13.76%
4.73
After Hours:
39.01
-0.09
-0.23%
Monopar Therapeutics Inc stock is traded at $39.10, with a volume of 46,159.
It is up +13.76% in the last 24 hours and down -11.92% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$34.37
Open:
$36.56
24h Volume:
46,159
Relative Volume:
0.81
Market Cap:
$238.61M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-17.00
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+26.54%
1M Performance:
-11.92%
6M Performance:
+768.89%
1Y Performance:
+5,035%
1-Day Range:
$34.50
$42.96
1-Week Range:
$29.49
$42.96
52-Week Range:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
39.10 | 238.61M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha
Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks
Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK
(MNPR) Trading Report - Stock Traders Daily
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St
Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics appoints new CFO - Investing.com
Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks
Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com
Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia
Monopar Therapeutics appoints new board member - Investing.com
Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK
Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks
Trend Tracker for (MNPR) - Stock Traders Daily
Copper wired: Monopar to electrify Wilson disease? - BioWorld Online
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat
Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World
Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat
What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat
Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire
Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - MSN
Up 1,000% In 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - Barchart
Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Piper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - MSN
(MNPR) Trading Advice - Stock Traders Daily
Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Brookline Capital Management Comments on MNPR Q1 Earnings - Defense World
Brookline Capital Management Predicts MNPR Q1 Earnings - MarketBeat
How To Know If Monopar Therapeutics Inc (NASDAQ:MNPR) Is Expensive At $24.46. - Marketing Sentinel
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Monopar Therapeutics Inc - GuruFocus.com
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - MSN
How the (MNPR) price action is used to our Advantage - Stock Traders Daily
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025 - Yahoo Finance
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):